请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
℡ 4000-520-616
℡ 4000-520-616
MedKoo/Foretinibfeatured/100mg/201372
产品编号:201372
市  场 价:¥3800.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$190.00
品      牌: MedKoo
公      司:MedKoo Biosciences, Inc
公司分类:
MedKoo/Foretinibfeatured/100mg/201372
商品介绍

Foretinib
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:201372

CAS#:849217-64-7

Description:Foretinib, also known as XL880 and GSK1363089, is an orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers.

Price and Availability

SizePriceShipping out timeQuantity
100mgUSD 1902 Weeks
200mgUSD 3502 Weeks
500mgUSD 7502 Weeks
1gUSD 12502 Weeks
2gUSD 22502 Weeks
5gUSD 49502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

Foretinib, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 201372Name: ForetinibCAS#: 849217-64-7Chemical Formula: C34H34F2N4O6Exact Mass: 632.24464Molecular Weight: 632.65377Elemental Analysis: C, 64.55; H, 5.42; F, 6.01; N, 8.86; O, 15.17

Synonym:XL880; XL 880; XL-880; GSK1363089; GSK 1363089; GSK-1363089; GSK089; EXEL2880; Foretinib.

IUPAC/Chemical Name:N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

InChi Key:CXQHYVUVSFXTMY-UHFFFAOYSA-N

InChi Code:InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)

SMILES Code:O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC=C(OC4=CC=NC5=CC(OCCCN6CCOCC6)=C(OC)C=C45)C(F)=C3

Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Bénard J. [ROS1 fusion proteins, targets offoretinib]. Bull Cancer. 2014 Jan 1;101(1):4. French. PubMed PMID:24649496.

2: Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J,Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ. Foretinib is apotent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci US A. 2013 Nov 26;110(48):19519-24. doi: 10.1073/pnas.1319583110. Epub2013 Nov 11. PubMed PMID: 24218589; PubMed Central PMCID: PMC3845150.

3: Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, LeeFC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R,Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor,in patients with metastatic gastric cancer. PLoS One. 2013;8(3):e54014.doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14. PubMed PMID:23516391; PubMed Central PMCID: PMC3597709.

4: Logan TF. Foretinib (XL880): c-MET inhibitor with activity inpapillary renal cell cancer. Curr Oncol Rep. 2013 Apr;15(2):83-90. doi:10.1007/s11912-013-0299-3. Review. PubMed PMID: 23408121.

5: Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL,Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH,Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R,Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, SrinivasanR. Phase II and biomarker study of the dual MET/VEGFR2 inhibitorforetinib in patients with papillary renal cell carcinoma. J Clin Oncol.2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3.PubMed PMID: 23213094; PubMed Central PMCID: PMC3532390.

6: Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, KeerH, Miles D, Müller T, Lorusso P. A Phase 1 dose-escalation study of thesafety and pharmacokinetics of once-daily oral foretinib, a multi-kinaseinhibitor, in patients with solid tumors. Invest New Drugs. 2013Jun;31(3):742-50. doi: 10.1007/s10637-012-9881-z. Epub 2012 Oct 6.PubMed PMID: 23054208.

7: Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN,Blumenschein G Jr. Phase II trial of single-agent foretinib (GSK1363089)in patients with recurrent or metastatic squamous cell carcinoma of thehead and neck. Invest New Drugs. 2013 Apr;31(2):417-24. doi:10.1007/s10637-012-9861-3. Epub 2012 Aug 24. PubMed PMID: 22918720;PubMed Central PMCID: PMC3589657.

8: Huynh H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activityand improves overall survival in preclinical models of hepatocellularcarcinoma. Angiogenesis. 2012 Mar;15(1):59-70. doi:10.1007/s10456-011-9243-z. Epub 2011 Dec 21. PubMed PMID: 22187171.

9: Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N,Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P. Mechanism ofaction of the multikinase inhibitor Foretinib. Cell Cycle. 2011 Dec1;10(23):4138-48. doi: 10.4161/cc.10.23.18323. Epub 2011 Dec 1. PubMedPMID: 22101270.

10: Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y,Yashiro M, Hirakawa K, Hirai M, Minami H. Foretinib (GSK1363089), amulti-kinase inhibitor of MET and VEGFRs, inhibits growth of gastriccancer cell lines by blocking inter-receptor tyrosine kinase networks.Invest New Drugs. 2012 Aug;30(4):1352-60. doi:10.1007/s10637-011-9699-0. Epub 2011 Jun 8. PubMed PMID: 21655918.

品牌介绍
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔